Bacteriophage Therapy: a review and the Portuguese landscape
DOI:
https://doi.org/10.65332/rpdi.v20.140Palavras-chave:
Bacteriophages, Phage Therapy, Antimicrobial Resistance, Chronic bacterial infections, Bacterial virusesResumo
This review provides a comprehensive overview of bacteriophage biology and classification, phage–bacteria interactions, and the mechanisms underlying phage-therapy efficacy, including its activity against biofilms and multidrug-resistant pathogens.
It further examines phage–antibiotic synergy, resistance dynamics, safety considerations, pharmacokinetic and pharmacodynamic aspects, and the role of phage banks.
Finally, the article discusses clinical evidence supporting phage therapy, emerging applications, and the Portuguese experience, highlighting regulatory, logistical, and clinical pathways that support the integration of phage therapy into modern infectious disease management.
Referências
1. Twort FW. An investigation on the nature of ultra-microscopic viruses. Bacteriophage. 2011;1(3):127–129. https://doi.org/10.4161/bact.1.3.16737 DOI: https://doi.org/10.4161/bact.1.3.16737
2. D'Herelle F. On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D'Herelle, presented by Mr. Roux. Res Microbiol. 2007;158(7):553–554. https://doi.org/10.1016/j.resmic.2007.07.005 DOI: https://doi.org/10.1016/j.resmic.2007.07.005
3. World Health Organization. WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS): global antibiotic resistance surveillance report. Geneva: World Health Organization; 2025.
4. Kortright KE, Chan BK, Koff JL, Turner PE. Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe. 2019;25(2):219–232. https://doi.org/10.1016/j.chom.2019.01.014 DOI: https://doi.org/10.1016/j.chom.2019.01.014
5. Grincho N, Mateus F, Silva P, Sousa H. Resistências aos antimicrobianos: flagelo socioeconómico do século XXI. Revista da UI IPSantarém. 2019;7(2):112–114. https://doi.org/10.25746/ruiips.v7.i2.19303
6. Clokie MRJ, Millard AD, Letarov AV, Heaphy S. Phages in nature. Bacteriophage. 2011;1(1):31–45. https://doi.org/10.4161/bact.1.1.14942 DOI: https://doi.org/10.4161/bact.1.1.14942
7. Fernández L, Gutiérrez D, García P, Rodríguez A. The perfect bacteriophage for therapeutic applications—a quick guide. Antibiotics. 2019;8(3):126. https://doi.org/10.3390/antibiotics8030126 DOI: https://doi.org/10.3390/antibiotics8030126
8. Comeau AM, Hatfull GF, Krisch HM, Lindell D, Mann NH, Prangishvili D. Exploring the prokaryotic virosphere. Res Microbiol. 2008;159(5):306–313. https://doi.org/10.1016/j.resmic.2008.05.001 DOI: https://doi.org/10.1016/j.resmic.2008.05.001
9. Turner D, Shkoporov AN, Lood C, Millard AD, Dutilh BE, Alfenas-Zerbini P, et al. Abolishment of morphology-based taxa and change to binomial species names: 2022 taxonomy update of the ICTV bacterial viruses subcommittee. Arch Virol. 2023;168(2):74. https://doi.org/10.1007/s00705-022-05694-2 DOI: https://doi.org/10.1007/s00705-022-05694-2
10. Veesler D, Cambillau C. A common evolutionary origin for tailed-bacteriophage functional modules and bacterial machineries. Microbiol Mol Biol Rev. 2011;75(3):423–433. https://doi.org/10.1128/MMBR.00014-11 DOI: https://doi.org/10.1128/MMBR.00014-11
11. Salmond GPC, Fineran PC. A century of the phage: past, present and future. Nat Rev Microbiol. 2015;13(12):777–786. https://doi.org/10.1038/nrmicro3564 DOI: https://doi.org/10.1038/nrmicro3564
12. Ofir G, Sorek R. Contemporary phage biology: from classic models to new insights. Cell. 2018;172(6):1260–1270. https://doi.org/10.1016/j.cell.2017.10.045 DOI: https://doi.org/10.1016/j.cell.2017.10.045
13. Gummalla VS, Zhang Y, Liao Y-T, Wu VCH. The role of temperate phages in bacterial pathogenicity. Microorganisms. 2023;11(3):541. https://doi.org/10.3390/microorganisms11030541 DOI: https://doi.org/10.3390/microorganisms11030541
14. Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2017;61(10):e00954-17. https://doi.org/10.1128/AAC.00954-17 DOI: https://doi.org/10.1128/AAC.00954-17
15. Hyman P, Abedon ST. Bacteriophage host range and bacterial resistance. In: Advances in Applied Microbiology. Vol 70. 2010. p. 217–248. https://doi.org/10.1016/S0065-2164(10)70007-1 DOI: https://doi.org/10.1016/S0065-2164(10)70007-1
16. Olawade DB, Fapohunda O, Egbon E, Ebiesuwa OA, Usman SO, Faronbi AO, et al. Phage therapy: a targeted approach to overcoming antibiotic resistance. Microb Pathog. 2024;197:107088. https://doi.org/10.1016/j.micpath.2024.107088 DOI: https://doi.org/10.1016/j.micpath.2024.107088
17. Labrie SJ, Samson JE, Moineau S. Bacteriophage resistance mechanisms. Nat Rev Microbiol. 2010;8(5):317–327. https://doi.org/10.1038/nrmicro2315 DOI: https://doi.org/10.1038/nrmicro2315
18. Bernheim A, Sorek R. The pan-immune system of bacteria: antiviral defence as a community resource. Nat Rev Microbiol. 2020;18(2):113–119. https://doi.org/10.1038/s41579-019-0278-2 DOI: https://doi.org/10.1038/s41579-019-0278-2
19. Rohde C, Resch G, Pirnay J-P, Blasdel B, Debarbieux L, Gelman D, et al. Expert opinion on three phage therapy related topics: bacterial phage resistance, phage training and prophages in bacterial production strains. Viruses. 2018;10(4):178. https://doi.org/10.3390/v10040178 DOI: https://doi.org/10.3390/v10040178
20. Hall AR, De Vos D, Friman V-P, Pirnay J-P, Buckling A. Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae. Appl Environ Microbiol. 2012;78(16):5646–5652. https://doi.org/10.1128/AEM.00757-12 DOI: https://doi.org/10.1128/AEM.00757-12
21. Mangalea MR, Duerkop BA. Fitness trade-offs resulting from bacteriophage resistance potentiate synergistic antibacterial strategies. Infect Immun. 2020;88(4):e00926-19. https://doi.org/10.1128/IAI.00926-19 DOI: https://doi.org/10.1128/IAI.00926-19
22. Egido JE, Costa AR, Aparicio-Maldonado C, Haas P-J, Brouns SJJ. Mechanisms and clinical importance of bacteriophage resistance. FEMS Microbiol Rev. 2022;46(1):fuab048. https://doi.org/10.1093/femsre/fuab048 DOI: https://doi.org/10.1093/femsre/fuab048
23. Sauer K, Stoodley P, Goeres DM, Hall-Stoodley L, Burmølle M, Stewart PS, et al. The biofilm life cycle: expanding the conceptual model of biofilm formation. Nat Rev Microbiol. 2022;20(10):608–620. https://doi.org/10.1038/s41579-022-00767-0 DOI: https://doi.org/10.1038/s41579-022-00767-0
24.Harper DR, Parracho HMRT, Walker J, Sharp R, Hughes G, Werthén M, et al. Bacteriophages and biofilms. Antibiotics. 2014;3(3):270–284. https://doi.org/10.3390/antibiotics3030270 DOI: https://doi.org/10.3390/antibiotics3030270
25. Pires DP, Melo LDR, Vilas Boas D, Sillankorva S, Azeredo J. Phage therapy as an alternative or complementary strategy to prevent and control biofilm-related infections. Curr Opin Microbiol. 2017;39:48–56. https://doi.org/10.1016/j.mib.2017.09.004
26. Meneses L, Brandão AC, Coenye T, Braga AC, Pires DP, Azeredo J. A systematic review of the use of bacteriophages for in vitro biofilm control. Eur J Clin Microbiol Infect Dis. 2023;42(8):919–928. https://doi.org/10.1007/s10096-023-04638-1 DOI: https://doi.org/10.1007/s10096-023-04638-1
27. Turner PE, Azeredo J, Buurman ET, Green S, Haaber JK, Haggstrom D, et al. Addressing the research and development gaps in modern phage therapy. PHAGE. 2024;5(1):30–39. https://doi.org/10.1089/phage.2023.0045 DOI: https://doi.org/10.1089/phage.2023.0045
28. Comeau AM, Tétart F, Trojet SN, Prère M-F, Krisch HM. Phage-antibiotic synergy (PAS): β-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS One. 2007;2(8):e799. https://doi.org/10.1371/journal.pone.0000799 DOI: https://doi.org/10.1371/journal.pone.0000799
29. Gordillo Altamirano FL, Barr JJ. Phage therapy in the postantibiotic era. Clin Microbiol Rev. 2019;32(2):e00066-18. https://doi.org/10.1128/CMR.00066-18 DOI: https://doi.org/10.1128/CMR.00066-18
30. Morrisette T, Kebriaei R, Lev K, Morales S, Rybak MJ. Bacteriophage therapeutics: a primer for clinicians on phage-antibiotic combinations. Pharmacotherapy. 2020;40(2):153–168. https://doi.org/10.1002/phar.2358 DOI: https://doi.org/10.1002/phar.2358
31. Supina BSI, Dennis JJ. The current landscape of phage–antibiotic synergistic (PAS) interactions. Antibiotics. 2025;14(6):545. https://doi.org/10.3390/antibiotics14060545 DOI: https://doi.org/10.3390/antibiotics14060545
32. Diallo K, Dublanchet A. Benefits of combined phage–antibiotic therapy for the control of antibiotic-resistant bacteria: a literature review. Antibiotics. 2022;11(7):839. https://doi.org/10.3390/antibiotics11070839 DOI: https://doi.org/10.3390/antibiotics11070839
33. Summers WC. Bacteriophage therapy. Annu Rev Microbiol. 2001;55:437–451. https://doi.org/10.1146/annurev.micro.55.1.437 DOI: https://doi.org/10.1146/annurev.micro.55.1.437
34. Lin DM, Koskella B, Lin HC. Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther. 2017;8(3):162–173. https://doi.org/10.4292/wjgpt.v8.i3.162 DOI: https://doi.org/10.4292/wjgpt.v8.i3.162
35. Łusiak-Szelachowska M, Weber-Dąbrowska B, Górski A. Bacteriophages and lysins in biofilm control. Virol Sin. 2020;35(2):125–133. https://doi.org/10.1007/s12250-019-00192-3 DOI: https://doi.org/10.1007/s12250-019-00192-3
36. Kever L, Hardy A, Luthe T, Hünnefeld M, Gätgens C, Milke L, et al. Aminoglycoside antibiotics inhibit phage infection by blocking an early step of the infection cycle. mBio. 2022;13(2):e00783-22. https://doi.org/10.1128/mbio.00783-22 DOI: https://doi.org/10.1128/mbio.00783-22
37. Abedon ST. Phage-antibiotic combination treatments: antagonistic impacts of antibiotics on the pharmacodynamics of phage therapy? Antibiotics. 2019;8(4):182. https://doi.org/10.3390/antibiotics8040182 DOI: https://doi.org/10.3390/antibiotics8040182
38. Jiang Z, Wei J, Liang Y, Peng N, Li Y. Aminoglycoside antibiotics inhibit mycobacteriophage infection. Antibiotics. 2020;9(10):714. https://doi.org/10.3390/antibiotics9100714 DOI: https://doi.org/10.3390/antibiotics9100714
39. Dimitriu T, Kurilovich E, Łapińska U, Severinov K, Pagliara S, Szczelkun MD, et al. Bacteriostatic antibiotics promote CRISPR-Cas adaptive immunity by enabling increased spacer acquisition. Cell Host Microbe. 2022;30(1):31–40.e5. https://doi.org/10.1016/j.chom.2021.11.014 DOI: https://doi.org/10.1016/j.chom.2021.11.014
40. Hille F, Richter H, Wong SP, Bratovič M, Ressel S, Charpentier E. The biology of CRISPR-Cas: backward and forward. Cell. 2018;172(6):1239–1259. https://doi.org/10.1016/j.cell.2017.11.032 DOI: https://doi.org/10.1016/j.cell.2017.11.032
41. Liu H, Li H, Liang Y, Du X, Yang C, Yang L, et al. Phage-delivered sensitisation with subsequent antibiotic treatment reveals sustained effect against antimicrobial resistant bacteria. Theranostics. 2020;10(14):6310–6321. https://doi.org/10.7150/thno.42573 DOI: https://doi.org/10.7150/thno.42573
42. Huh K, Chung DR, Ha YE, Ko J-H, Kim S-H, Kim M-J, et al. Impact of difficult-to-treat resistance in Gram-negative bacteremia on mortality: retrospective analysis of nationwide surveillance data. Clin Infect Dis. 2020;71(9):e487–e496. https://doi.org/10.1093/cid/ciaa084 DOI: https://doi.org/10.1093/cid/ciaa084
43. Sati H, Carrara E, Savoldi A, Hansen P, Garlasco J, Campagnaro E, et al.; WHO Bacterial Priority Pathogens List Advisory Group. The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance. Lancet Infect Dis. 2025;25(9):1033–1043. https://doi.org/10.1016/S1473-3099(25)00118-5 DOI: https://doi.org/10.1016/S1473-3099(25)00118-5
44. Cisek AA, Dąbrowska I, Gregorczyk KP, Wyżewski Z. Phage therapy in bacterial infections treatment: one hundred years after the discovery of bacteriophages. Curr Microbiol. 2017;74(2):277–283. https://doi.org/10.1007/s00284-016-1166-x DOI: https://doi.org/10.1007/s00284-016-1166-x
45. Pires DP, Vilas Boas D, Sillankorva S, Azeredo J. Phage therapy: a step forward in the treatment of Pseudomonas aeruginosa infections. J Virol. 2015;89(15):7449–7456. https://doi.org/10.1128/jvi.00385-15 DOI: https://doi.org/10.1128/JVI.00385-15
46. Moller AG, Winston K, Ji S, Wang J, Hargita Davis MN, Solís-Lemus CR, et al. Genes influencing phage host range in Staphylococcus aureus on a species-wide scale. mSphere. 2021;6(1):e01263-20. https://doi.org/10.1128/mSphere.01263-20 DOI: https://doi.org/10.1128/mSphere.01263-20
47. Haudiquet M, Le Bris J, Nucci A, Bonnin RA, Domingo-Calap P, Rocha EPC, et al. Capsules and their traits shape phage susceptibility and plasmid conjugation efficiency. Nat Commun. 2024;15:2032. https://doi.org/10.1038/s41467-024-46147-5 DOI: https://doi.org/10.1038/s41467-024-46147-5
48. Bai J, Raustad N, Denoncourt J, van Opijnen T, Geisinger E. Genome-wide phage susceptibility analysis in Acinetobacter baumannii reveals capsule modulation strategies that determine phage infectivity. PLoS Pathog. 2023;19(3):e1010928. https://doi.org/10.1371/journal.ppat.1010928 DOI: https://doi.org/10.1371/journal.ppat.1010928
49. Resch G, Brives C, Debarbieux L, Hodges FE, Kirchhelle C, Laurent F, et al. Between centralization and fragmentation: the past, present, and future of phage collections. PHAGE. 2024;5(1):22–29. https://doi.org/10.1089/phage.2023.0043 DOI: https://doi.org/10.1089/phage.2023.0043
50. Nagel T, Musila L, Muthoni M, Nikolich M, Nakavuma JL, Clokie MRJ. Phage banks as potential tools to rapidly and cost-effectively manage antimicrobial resistance in the developing world. Curr Opin Virol. 2022;53:101208. https://doi.org/10.1016/j.coviro.2022.101208 DOI: https://doi.org/10.1016/j.coviro.2022.101208
51. Żaczek M, Górski A, Weber-Dąbrowska B, Letkiewicz S, Fortuna W, Rogóż P, et al. A thorough synthesis of phage therapy unit activity in Poland—its history, milestones and international recognition. Viruses. 2022;14(6):1170. https://doi.org/10.3390/v14061170 DOI: https://doi.org/10.3390/v14061170
52. Malik DJ, Sokolov IJ, Vinner GK, Mancuso F, Cinquerrui S, Vladisavljevic GT, et al. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. Adv Colloid Interface Sci. 2017;249:100–133. https://doi.org/10.1016/j.cis.2017.05.014 DOI: https://doi.org/10.1016/j.cis.2017.05.014
53. Bonilla N, Barr JJ. Phage on tap: a quick and efficient protocol for the preparation of bacteriophage laboratory stocks. Methods Mol Biol. 2018;1838:37–46. https://doi.org/10.1007/978-1-4939-8682-8_4 DOI: https://doi.org/10.1007/978-1-4939-8682-8_4
54. Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. Antimicrob Agents Chemother. 2001;45(3):649–659. https://doi.org/10.1128/AAC.45.3.649-659.2001 DOI: https://doi.org/10.1128/AAC.45.3.649-659.2001
55. Hanlon GW. Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Int J Antimicrob Agents. 2007;30(2):118–128. https://doi.org/10.1016/j.ijantimicag.2007.04.006 DOI: https://doi.org/10.1016/j.ijantimicag.2007.04.006
56. Chegini Z, Khoshbayan A, Taati Moghadam M, Farahani I, Jazireian P, Shariati A. Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review. Ann Clin Microbiol Antimicrob. 2020;19:45. https://doi.org/10.1186/s12941-020-00389-5 DOI: https://doi.org/10.1186/s12941-020-00389-5
57. Pires DP, Melo LDR, Vilas Boas D, Sillankorva S, Azeredo J. Phage therapy as an alternative or complementary strategy to prevent and control biofilm-related infections. Curr Opin Microbiol. 2017;39:48–56. https://doi.org/10.1016/j.mib.2017.09.004 DOI: https://doi.org/10.1016/j.mib.2017.09.004
58. Waters EM, Neill DR, Kaman B, Sahota JS, Clokie MRJ, Winstanley C, et al. Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa. Thorax. 2017;72(7):666–667. https://doi.org/10.1136/thoraxjnl-2016-209265 DOI: https://doi.org/10.1136/thoraxjnl-2016-209265
59. Chhibber S, Kaur T, Kaur S. Co-therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infections. PLoS One. 2013;8(2):e56022. https://doi.org/10.1371/journal.pone.0056022 DOI: https://doi.org/10.1371/journal.pone.0056022
60. Kifelew LG, Warner MS, Morales S, Vaughan L, Woodman R, Fitridge R, et al. Efficacy of phage cocktail AB-SA01 therapy in diabetic mouse wound infections caused by multidrug-resistant Staphylococcus aureus. BMC Microbiol. 2020;20:204. https://doi.org/10.1186/s12866-020-01891-8 DOI: https://doi.org/10.1186/s12866-020-01891-8
61. Fish R, Kutter E, Wheat G, Blasdel B, Kutateladze M, Kuhl S. Bacteriophage treatment of intransigent diabetic toe ulcers: a case series. J Wound Care. 2016;25(7 Suppl):S27–S33. https://doi.org/10.12968/jowc.2016.25.7.S27 DOI: https://doi.org/10.12968/jowc.2016.25.Sup7.S27
62. Law N, Logan C, Yung G, Furr CLL, Lehman SM, Morales S, et al. Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient. Infection. 2019;47(4):665–668. https://doi.org/10.1007/s15010-019-01319-0
63. McCallin S, Sacher JC, Zheng J, Chan BK. Current state of compassionate phage therapy. Viruses. 2019;11(4):343. https://doi.org/10.3390/v11040343 DOI: https://doi.org/10.3390/v11040343
64. Pires DP, Costa AR, Pinto G, Meneses L, Azeredo J. Current challenges and future opportunities of phage therapy. FEMS Microbiol Rev. 2020;44(6):684–700. https://doi.org/10.1093/femsre/fuaa017
65. Pires DP, Meneses L, Brandão AC, Azeredo J. An overview of the current state of phage therapy for the treatment of biofilm-related infections. Curr Opin Virol. 2022;53:101209. https://doi.org/10.1016/j.coviro.2022.101209
66. Eschweiler J, Fischer C, Migliorini F, Greven J, Mendel T, Kobbe P, et al. Is a bacteriophage approach for musculoskeletal infection management an alternative to conventional therapy? Life. 2025;15(10):1534. https://doi.org/10.3390/life15101534 DOI: https://doi.org/10.3390/life15101534
67. Cammuso MT, Cook BWM, Cameron DW, Ryan S, Tamayo M, Peters MJ, et al. First use of phage therapy in Canada for the treatment of a life-threatening, multidrug-resistant Staphylococcus epidermidis periprosthetic joint infection. Viruses. 2025;17(8):1118. https://doi.org/10.3390/v17081118 DOI: https://doi.org/10.3390/v17081118
68. Wahl P, Schläppi M, Loganathan A, Uçkay I, Hodel S, Fritz B, et al. Bacteriophage therapy created the necessary conditions for successful antibiotic suppression in a periprosthetic hip joint infection: a case report. Front Med (Lausanne). 2025;12:1564369. https://doi.org/10.3389/fmed.2025.1564369 DOI: https://doi.org/10.3389/fmed.2025.1564369
69. Doub JB, Chan B, Johnson AJ. Salphage: salvage bacteriophage therapy for a chronic Enterococcus faecalis prosthetic joint infection. IDCases. 2023;33:e01854. https://doi.org/10.1016/j.idcr.2023.e01854 DOI: https://doi.org/10.1016/j.idcr.2023.e01854
70. Doub JB, Ng VY, Lee M, Chi A, Lee A, Würstle S, et al. Salphage: salvage bacteriophage therapy for recalcitrant MRSA prosthetic joint infection. Antibiotics. 2022;11(5):616. https://doi.org/10.3390/antibiotics11050616 DOI: https://doi.org/10.3390/antibiotics11050616
71. Doub JB, Shishido A, Srikumaran U, Haskoor J, Tran-Nguyen P, Lee M, et al. Salphage: salvage bacteriophage therapy for a recalcitrant Klebsiella pneumoniae prosthetic shoulder infection—a case report. Acta Orthop. 2022;93:756–759. https://doi.org/10.2340/17453674.2022.4579 DOI: https://doi.org/10.2340/17453674.2022.4579
72. Ferry T, Kolenda C, Laurent F, Leboucher G, Merabishvilli M, Djebara S, et al. Personalized bacteriophage therapy to treat pandrug-resistant spinal Pseudomonas aeruginosa infection. Nat Commun. 2022;13:4239. https://doi.org/10.1038/s41467-022-31837-9 DOI: https://doi.org/10.1038/s41467-022-31837-9
73. Schoeffel J, Wang EW, Gill D, Frackler J, Horne B, Manson T, et al. Successful use of salvage bacteriophage therapy for a recalcitrant MRSA knee and hip prosthetic joint infection. Pharmaceuticals. 2022;15(2):177. https://doi.org/10.3390/ph15020177 DOI: https://doi.org/10.3390/ph15020177
74. Eskenazi A, Lood C, Wubbolts J, Hites M, Balarjishvili N, Leshkasheli L, et al. Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant Klebsiella pneumoniae. Nat Commun. 2022;13:302. https://doi.org/10.1038/s41467-021-27656-z DOI: https://doi.org/10.1038/s41467-021-27656-z
75. Racenis K, Rezevska D, Madelane M, Lavrinovics E, Djebara S, Petersons A, et al. Use of phage cocktail BFC 1.10 in combination with ceftazidime-avibactam in the treatment of multidrug-resistant Pseudomonas aeruginosa femur osteomyelitis—a case report. Front Med (Lausanne). 2022;9:851310. https://doi.org/10.3389/fmed.2022.851310 DOI: https://doi.org/10.3389/fmed.2022.851310
76. Neuts AS, Berkhout HJ, Hartog A, Goosen JHM. Bacteriophage therapy cures a recurrent Enterococcus faecalis infected total hip arthroplasty? A case report. Acta Orthop. 2021;92(6):678–680. https://doi.org/10.1080/17453674.2021.1968714 DOI: https://doi.org/10.1080/17453674.2021.1968714
77. Ferry T, Kolenda C, Batailler C, Gaillard R, Gustave CA, Lustig S, et al. Case report: arthroscopic “debridement antibiotics and implant retention” with local injection of personalized phage therapy to salvage a relapsing Pseudomonas aeruginosa prosthetic knee infection. Front Med (Lausanne). 2021;8:569159. https://doi.org/10.3389/fmed.2021.569159 DOI: https://doi.org/10.3389/fmed.2021.569159
78. Doub JB, Ng VY, Wilson E, Corsini L, Chan BK. Successful treatment of a recalcitrant Staphylococcus epidermidis prosthetic knee infection with intraoperative bacteriophage therapy. Pharmaceuticals. 2021;14(3):231. https://doi.org/10.3390/ph14030231 DOI: https://doi.org/10.3390/ph14030231
79. Cano EJ, Caflisch KM, Bollyky PL, Van Belleghem JD, Patel R, Fackler J, et al. Phage therapy for limb-threatening prosthetic knee Klebsiella pneumoniae infection: case report and in vitro characterization of anti-biofilm activity. Clin Infect Dis. 2021;73(1):e144–e151. https://doi.org/10.1093/cid/ciaa705 DOI: https://doi.org/10.1093/cid/ciaa705
80. Ramirez-Sanchez C, Gonzales F, Buckley M, Biswas B, Henry M, Deschenes MV, et al. Successful treatment of Staphylococcus aureus prosthetic joint infection with bacteriophage therapy. Viruses. 2021;13(6):1182. https://doi.org/10.3390/v13061182 DOI: https://doi.org/10.3390/v13061182
81. Van Nieuwenhuyse B, Galant C, Brichard B, Docquier PL, Djebara S, Pirnay JP, et al. A case of in situ phage therapy against Staphylococcus aureus in a bone allograft polymicrobial biofilm infection: outcomes and phage-antibiotic interactions. Viruses. 2021;13(10):1898. https://doi.org/10.3390/v13101898 DOI: https://doi.org/10.3390/v13101898
82. Ferry T, Kolenda C, Batailler C, Gustave CA, Lustig S, Malatray M, et al. Phage therapy as adjuvant to conservative surgery and antibiotics to salvage patients with relapsing S. aureus prosthetic knee infection. Front Med (Lausanne). 2020;7:570572. https://doi.org/10.3389/fmed.2020.570572 DOI: https://doi.org/10.3389/fmed.2020.570572
83. Doub JB, Ng VY, Johnson AJ, Slomka M, Fackler J, Horne B, et al. Salvage bacteriophage therapy for a chronic MRSA prosthetic joint infection. Antibiotics. 2020;9(5):241. https://doi.org/10.3390/antibiotics9050241 DOI: https://doi.org/10.3390/antibiotics9050241
84. Onsea J, Soentjens P, Djebara S, Merabishvili M, Depypere M, Spriet I, et al. Bacteriophage application for difficult-to-treat musculoskeletal infections: development of a standardized multidisciplinary treatment protocol. Viruses. 2019;11(10):891. https://doi.org/10.3390/v11100891 DOI: https://doi.org/10.3390/v11100891
85. Nir-Paz R, Gelman D, Khouri A, Sisson BM, Fackler J, Alkalay-Oren S, et al. Successful treatment of antibiotic-resistant, polymicrobial bone infection with bacteriophages and antibiotics combination. Clin Infect Dis. 2019;69(11):2015–2018. https://doi.org/10.1093/cid/ciz222 DOI: https://doi.org/10.1093/cid/ciz222
86. Ferry T, Leboucher G, Fevre C, Herry Y, Conrad A, Josse J, et al. Salvage debridement, antibiotics and implant retention (“DAIR”) with local injection of a selected cocktail of bacteriophages: is it an option for an elderly patient with relapsing Staphylococcus aureus prosthetic-joint infection? Open Forum Infect Dis. 2018;5(11):ofy269. https://doi.org/10.1093/ofid/ofy269 DOI: https://doi.org/10.1093/ofid/ofy269
87. Ferry T, Boucher F, Fevre C, Perpoint T, Chateau J, Petitjean C, et al. Innovations for the treatment of a complex bone and joint infection due to XDR Pseudomonas aeruginosa including local application of a selected cocktail of bacteriophages. J Antimicrob Chemother. 2018;73(10):2901–2903. https://doi.org/10.1093/jac/dky263 DOI: https://doi.org/10.1093/jac/dky263
88. Fish R, Kutter E, Bryan D, Wheat G, Kuhl S. Resolving digital staphylococcal osteomyelitis using bacteriophage—a case report. Antibiotics. 2018;7(4):87. https://doi.org/10.3390/antibiotics7040087 DOI: https://doi.org/10.3390/antibiotics7040087
89. Eiferman V, Vion PA, Bleibtreu A. Phage therapy as a rescue treatment for recurrent Pseudomonas aeruginosa Bentall infection. Viruses. 2025;17(1):123. https://doi.org/10.3390/v17010123 DOI: https://doi.org/10.3390/v17010123
90. Hameed I, Ahmed A, Gandhi S, Nassiri N, Steinbacher DM, Vallabhajosyula P. Successful investigational phage therapy for pan-resistant bacterial mediastinitis following type II hybrid aortic arch replacement. JACC Case Rep. 2024;29:102816. https://doi.org/10.1016/j.jaccas.2024.102816 DOI: https://doi.org/10.1016/j.jaccas.2024.102816
91. Racenis K, Lacis J, Rezevska D, Mukane L, Vilde A, Putnins I, et al. Successful bacteriophage-antibiotic combination therapy against multidrug-resistant Pseudomonas aeruginosa left ventricular assist device driveline infection. Viruses. 2023;15(5):1210. https://doi.org/10.3390/v15051210 DOI: https://doi.org/10.3390/v15051210
92. Rojas SV, Junghans S, Fox H, Lazouski K, Schramm R, Morshuis M, et al. Bacteriophage-enriched galenic for intrapericardial ventricular assist device infection. Antibiotics. 2022;11(5):602. https://doi.org/10.3390/antibiotics11050602 DOI: https://doi.org/10.3390/antibiotics11050602
93. Grambow E, Junghans S, Kröger JC, Reisinger EC, Krause BJ, Groß J. Treatment of an infected TEVAR with extra- and endovascular bacteriophage application. EJVES Vasc Forum. 2022;56:20–23. https://doi.org/10.1016/j.ejvsvf.2022.02.004 DOI: https://doi.org/10.1016/j.ejvsvf.2022.02.004
94. Püschel A, Skusa R, Bollensdorf A, Gross J. Local treatment of driveline infection with bacteriophages. Antibiotics. 2022;11(10):1310. https://doi.org/10.3390/antibiotics11101310 DOI: https://doi.org/10.3390/antibiotics11101310
95. Rubalskii E, Ruemke S, Salmoukas C, Boyle EC, Warnecke G, Tudorache I, et al. Bacteriophage therapy for critical infections related to cardiothoracic surgery. Antibiotics. 2020;9(5):232. https://doi.org/10.3390/antibiotics9050232 DOI: https://doi.org/10.3390/antibiotics9050232
96. Aslam S, Pretorius V, Lehman SM, Morales S, Schooley RT. Novel bacteriophage therapy for treatment of left ventricular assist device infection. J Heart Lung Transplant. 2019;38(4):475–476. https://doi.org/10.1016/j.healun.2019.01.001 DOI: https://doi.org/10.1016/j.healun.2019.01.001
97. Gilbey T, Ho J, Cooley LA, Petrovic Fabijan A, Iredell JR. Adjunctive bacteriophage therapy for prosthetic valve endocarditis due to Staphylococcus aureus. Med J Aust. 2019;211(3):142–143.e1. https://doi.org/10.5694/mja2.50274 DOI: https://doi.org/10.5694/mja2.50274
98. Chan BK, Turner PE, Kim S, Mojibian HR, Elefteriades JA, Narayan D. Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol Med Public Health. 2018;2018(1):60–66. https://doi.org/10.1093/emph/eoy005 DOI: https://doi.org/10.1093/emph/eoy005
99. Yang Y, Tan X, Xiong M, Liu Z, Lu S, Ge H, et al. A case report of bacteriophage therapy for the treatment of lung infection due to carbapenem-resistant Pseudomonas aeruginosa. Sci Rep. 2025;15. https://doi.org/10.1038/s41598-025-17510-3 DOI: https://doi.org/10.1038/s41598-025-17510-3
100. Teney C, Poupelin JC, Briot T, Le Bouar M, Fevre C, Daviet F, et al. Phage therapy in a burn patient colonized with extensively drug-resistant Pseudomonas aeruginosa responsible for relapsing ventilator-associated pneumonia and bacteremia. Viruses. 2024;16(7):1080. https://doi.org/10.3390/v16071080 DOI: https://doi.org/10.3390/v16071080
101. Köhler T, Luscher A, Falconnet L, Resch G, McBride R, Mai Q-A, et al. Personalized aerosolised bacteriophage treatment of a chronic lung infection due to multidrug-resistant Pseudomonas aeruginosa. Nat Commun. 2023;14:3629. https://doi.org/10.1038/s41467-023-39370-z DOI: https://doi.org/10.1038/s41467-023-39370-z
102. Li L, Zhong Q, Zhao Y, Bao J, Liu B, Zhong Z, et al. First-in-human application of double-stranded RNA bacteriophage in the treatment of pulmonary Pseudomonas aeruginosa infection. Microb Biotechnol. 2023;16(5):862–867. https://doi.org/10.1111/1751-7915.14217 DOI: https://doi.org/10.1111/1751-7915.14217
103. Haidar G, Chan BK, Cho ST, Hughes Kramer K, Nordstrom HR, Wallace NR, et al. Phage therapy in a lung transplant recipient with cystic fibrosis infected with multidrug-resistant Burkholderia multivorans. Transpl Infect Dis. 2023;25:e14041. https://doi.org/10.1111/tid.14041 DOI: https://doi.org/10.1111/tid.14041
104. Levêque M, Cassir N, Mathias F, Fevre C, Daviet F, Bermudez J, et al. Refractory Pseudomonas aeruginosa bronchopulmonary infection after lung transplantation for common variable immunodeficiency despite maximal treatment including IgM/IgA-enriched immunoglobulins and bacteriophage therapy. Infect Drug Resist. 2023;16:4265–4271. https://doi.org/10.2147/IDR.S413900 DOI: https://doi.org/10.2147/IDR.S413900
105. Li J, Yan B, He B, Li L, Zhou X, Wu N, et al. Development of phage resistance in multidrug-resistant Klebsiella pneumoniae is associated with reduced virulence: a case report of a personalised phage therapy. Clin Microbiol Infect. 2023;29(12):1601.e1–1601.e7. https://doi.org/10.1016/j.cmi.2023.08.022 DOI: https://doi.org/10.1016/j.cmi.2023.08.022
106. Chen P, Liu Z, Tan X, Wang H, Liang Y, Kong Y, et al. Bacteriophage therapy for empyema caused by carbapenem-resistant Pseudomonas aeruginosa. Biosci Trends. 2022;16(2):158–162. https://doi.org/10.5582/bst.2022.01147 DOI: https://doi.org/10.5582/bst.2022.01147
107. Wu N, Dai J, Guo M, Li J, Zhou X, Li F, et al. Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 patients. Emerg Microbes Infect. 2021;10(1):612–618. https://doi.org/10.1080/22221751.2021.1902754 DOI: https://doi.org/10.1080/22221751.2021.1902754
108. Maddocks S, Fabijan AP, Ho J, Lin RCY, Ben Zakour NL, Dugan C, et al. Bacteriophage therapy of ventilator-associated pneumonia and empyema caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2019;200(9):1179–1181. https://doi.org/10.1164/rccm.201904-0839LE DOI: https://doi.org/10.1164/rccm.201904-0839LE
109. Aslam S, Courtwright AM, Koval C, Lehman SM, Morales S, Furr CLL, et al. Early clinical experience of bacteriophage therapy in 3 lung transplant recipients. Am J Transplant. 2019;19(9):2631–2639. https://doi.org/10.1111/ajt.15503 DOI: https://doi.org/10.1111/ajt.15503
110. Law N, Logan C, Yung G, Furr CLL, Lehman SM, Morales S, et al. Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient. Infection. 2019;47(4):665–668. https://doi.org/10.1007/s15010-019-01319-0 DOI: https://doi.org/10.1007/s15010-019-01319-0
111. Cook JD, Hooey PB, Salazar KC, Clark JR, Jain U, Fernando C, et al. Results of TOR001: an open-label single patient study using targeted bacteriophage therapy for the treatment of chronic urinary tract infection. Int J Antimicrob Agents. 2025;66:107613. https://doi.org/10.1016/j.ijantimicag.2025.107613 DOI: https://doi.org/10.1016/j.ijantimicag.2025.107613
112. Cesta N, Fusco A, Ferretti C, Materazzi A, Altieri A, D'Agostini C, et al. Bacteriophage-enhanced doxycycline activity against Escherichia coli in chronic bacterial prostatitis. Int J Antimicrob Agents. 2025;66:107571. https://doi.org/10.1016/j.ijantimicag.2025.107571 DOI: https://doi.org/10.1016/j.ijantimicag.2025.107571
113. Johri AV, Johri P, Hoyle N, Nadareishvili L, Pipia L, Nizharadze D. Case report: successful treatment of recurrent E. coli infection with bacteriophage therapy for patient suffering from chronic bacterial prostatitis. Front Pharmacol. 2023;14:1243824. https://doi.org/10.3389/fphar.2023.1243824 DOI: https://doi.org/10.3389/fphar.2023.1243824
114. Le T, Nang SC, Zhao J, Yu HH, Li J, Gill JJ, et al. Therapeutic potential of intravenous phage as standalone therapy for recurrent drug-resistant urinary tract infections. Antimicrob Agents Chemother. 2023;67:e00037-23. https://doi.org/10.1128/aac.00037-23 DOI: https://doi.org/10.1128/aac.00037-23
115. Johri AV, Johri P, Hoyle N, Pipia L, Nadareishvili L, Nizharadze D. Case report: chronic bacterial prostatitis treated with phage therapy after multiple failed antibiotic treatments. Front Pharmacol. 2021;12:692614. https://doi.org/10.3389/fphar.2021.692614 DOI: https://doi.org/10.3389/fphar.2021.692614
116. Rostkowska OM, Międzybrodzki R, Miszewska-Szyszkowska D, Górski A, Durlik M. Treatment of recurrent urinary tract infections in a 60-year-old kidney transplant recipient: the use of phage therapy. Transpl Infect Dis. 2021;23:e13391. https://doi.org/10.1111/tid.13391 DOI: https://doi.org/10.1111/tid.13391
117. Terwilliger A, Clark J, Karris M, Hernandez-Santos H, Green S, Aslam S, et al. Phage therapy related microbial succession associated with successful clinical outcome for a recurrent urinary tract infection. Viruses. 2021;13(10):2049. https://doi.org/10.3390/v13102049 DOI: https://doi.org/10.3390/v13102049
118. Bao J, Wu N, Zeng Y, Chen L, Li L, Yang L, et al. Non-active antibiotic and bacteriophage synergism to successfully treat recurrent urinary tract infection caused by extensively drug-resistant Klebsiella pneumoniae. Emerg Microbes Infect. 2020;9(1):771–774. https://doi.org/10.1080/22221751.2020.1747950 DOI: https://doi.org/10.1080/22221751.2020.1747950
119. Kuipers S, Ruth MM, Mientjes M, de Sévaux RGL, van Ingen J. A Dutch case report of successful treatment of chronic relapsing urinary tract infection with bacteriophages in a renal transplant patient. Antimicrob Agents Chemother. 2020;64(1):e01281-19. https://doi.org/10.1128/AAC.01281-19 DOI: https://doi.org/10.1128/AAC.01281-19
120. Khawaldeh A, Morales S, Dillon B, Alavidze Z, Ginn AN, Thomas L, et al. Bacteriophage therapy for refractory Pseudomonas aeruginosa urinary tract infection. J Med Microbiol. 2011;60(Pt 11):1697–1700. https://doi.org/10.1099/jmm.0.029744-0 DOI: https://doi.org/10.1099/jmm.0.029744-0
121. Letkiewicz S, Międzybrodzki R, Fortuna W, Weber-Dąbrowska B, Górski A. Eradication of Enterococcus faecalis by phage therapy in chronic bacterial prostatitis—case report. Folia Microbiol (Praha). 2009;54(5):457–461. https://doi.org/10.1007/s12223-009-0064-z DOI: https://doi.org/10.1007/s12223-009-0064-z
122. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284(5418):1318–1322. https://doi.org/10.1126/science.284.5418.1318 DOI: https://doi.org/10.1126/science.284.5418.1318
123. Zimmerli W, Sendi P. Orthopaedic biofilm infections. APMIS. 2017;125(4):353–364. https://doi.org/10.1111/apm.12687 DOI: https://doi.org/10.1111/apm.12687
124. Arciola CR, Campoccia D, Ehrlich GD, Montanaro L. Biofilm-based implant infections in orthopaedics. Adv Exp Med Biol. 2015;830:29–46. https://doi.org/10.1007/978-3-319-11038-7_2 DOI: https://doi.org/10.1007/978-3-319-11038-7_2
125. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67–74. https://doi.org/10.1038/nrd2153 DOI: https://doi.org/10.1038/nrd2153
126. Abedon S, Thomas-Abedon C. Phage therapy pharmacology. Curr Pharm Biotechnol. 2010;11(1):28–47. https://doi.org/10.2174/138920110790725410 DOI: https://doi.org/10.2174/138920110790725410
127. Ibrahim R, Aranjani JM, Kalikot Valappil V, Nair G. Unveiling the potential bacteriophage therapy: a systematic review. Future Sci OA. 2025;11:2468114. https://doi.org/10.1080/20565623.2025.2468114 DOI: https://doi.org/10.1080/20565623.2025.2468114
128. Wang H, Yang Y, Xu Y, Chen Y, Zhang W, Liu T, et al. Phage-based delivery systems: engineering, applications, and challenges in nanomedicines. J Nanobiotechnol. 2024;22:365. https://doi.org/10.1186/s12951-024-02576-4 DOI: https://doi.org/10.1186/s12951-024-02576-4
129. Abedon ST, Danis-Wlodarczyk KM, Wozniak DJ. Phage cocktail development for bacteriophage therapy: toward improving spectrum of activity breadth and depth. Pharmaceuticals. 2021;14(10):1019. https://doi.org/10.3390/ph14101019 DOI: https://doi.org/10.3390/ph14101019
130. Pirnay J-P, De Vos D, Verbeken G, Merabishvili M, Chanishvili N, Vaneechoutte M, et al. The phage therapy paradigm: prêt-à-porter or sur-mesure? Pharm Res. 2011;28(4):934–937. https://doi.org/10.1007/s11095-010-0313-5 DOI: https://doi.org/10.1007/s11095-010-0313-5
131. Aslam S, Lampley E, Wooten D, Karris M, Benson C, Strathdee S, et al. Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States. Open Forum Infect Dis. 2020;7(9):ofaa389. https://doi.org/10.1093/ofid/ofaa389 DOI: https://doi.org/10.1093/ofid/ofaa389
132. Verbeken G, Pirnay J-P, Lavigne R, Jennes S, De Vos D, Casteels M, et al. Call for a dedicated European legal framework for bacteriophage therapy. Arch Immunol Ther Exp (Warsz). 2014;62(2):117–129. https://doi.org/10.1007/s00005-014-0269-y DOI: https://doi.org/10.1007/s00005-014-0269-y
133. Heyse S, Hanna LF, Woolston J, Sulakvelidze A, Charbonneau D. Bacteriophage cocktail for biocontrol of Salmonella in dried pet food. J Food Prot. 2015;78(1):97–103. https://doi.org/10.4315/0362-028X.JFP-14-041 DOI: https://doi.org/10.4315/0362-028X.JFP-14-041
134. Magnone JP, Marek PJ, Sulakvelidze A, Senecal AG. Additive approach for inactivation of Escherichia coli O157:H7, Salmonella, and Shigella spp. on contaminated fresh fruits and vegetables using bacteriophage cocktail and produce wash. J Food Prot. 2013;76(8):1336–1341. https://doi.org/10.4315/0362-028X.JFP-12-517 DOI: https://doi.org/10.4315/0362-028X.JFP-12-517
135. Roncolato EC, Campos LB, Pessenda G, Costa e Silva L, Furtado GP, Barbosa JE. Phage display as a novel promising antivenom therapy: a review. Toxicon. 2015;93:79–84. https://doi.org/10.1016/j.toxicon.2014.11.001 DOI: https://doi.org/10.1016/j.toxicon.2014.11.001
136. Siopi M, Skliros D, Paranos P, Koumasi N, Flemetakis E, Pournaras S, et al. Pharmacokinetics and pharmacodynamics of bacteriophage therapy: a review with a focus on multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Rev. 2024;37(4):e00044-24. https://doi.org/10.1128/cmr.00044-24 DOI: https://doi.org/10.1128/cmr.00044-24
137. Blasco L, Bleriot I, Fernández-Grela P, Paño-Pardo JR, Oteo-Iglesias J, Tomás M. Estudios farmacocinéticos y farmacodinámicos de la fagoterapia. Farm Hosp. 2025;49(5):407–412. https://doi.org/10.1016/j.farma.2025.04.003 DOI: https://doi.org/10.1016/j.farma.2025.04.003
138. Fuerst-Wilmes M, Respondek V, Schramm M, Lilienthal N, Buss K, Duechting A. Regulation of phage therapy medicinal products: developments, challenges, and opportunities. Front Cell Infect Microbiol. 2025;15:1631359. https://doi.org/10.3389/fcimb.2025.1631359 DOI: https://doi.org/10.3389/fcimb.2025.1631359
139. Nang SC, Lin Y-W, Petrovic Fabijan A, Chang RYK, Rao GG, Iredell J, et al. Pharmacokinetics/pharmacodynamics of phage therapy: a major hurdle to clinical translation. Clin Microbiol Infect. 2023;29(6):702–709. https://doi.org/10.1016/j.cmi.2023.01.021 DOI: https://doi.org/10.1016/j.cmi.2023.01.021
140. Holger D, Kebriaei R, Morrisette T, Lev K, Alexander J, Rybak M. Clinical pharmacology of bacteriophage therapy: a focus on multidrug-resistant Pseudomonas aeruginosa infections. Antibiotics. 2021;10(5):556. https://doi.org/10.3390/antibiotics10050556 DOI: https://doi.org/10.3390/antibiotics10050556
141. Knezevic P, Hoyle NS, Matsuzaki S, Gorski A. Editorial: advances in phage therapy: present challenges and future perspectives. Front Microbiol. 2021;12:701898. https://doi.org/10.3389/fmicb.2021.701898 DOI: https://doi.org/10.3389/fmicb.2021.701898
142. Pirnay JP. Phage therapy in the year 2035. Front Microbiol. 2020;11:1171. https://doi.org/10.3389/fmicb.2020.01171 DOI: https://doi.org/10.3389/fmicb.2020.01171
143. INFARMED — Autoridade Nacional do Medicamento e Produtos de Saúde, I.P. Deliberação n.º 112/CD/2024: norma orientadora sobre a utilização de medicamentos manipulados para terapia fágica em contexto hospitalar — preparações magistrais de bacteriófagos. Lisboa: INFARMED; 2024 Nov 15. https://www.infarmed.pt/documents/15786/9697484/2024-11-15_Delibera%C3%A7%C3%A3o_112_CD_2024/d0424242-a103-1256-cd7d-526aaf12dfac?version=1.0
144. University of Minho. UMinho announces creation of Therapeutic Phage Production Laboratory [Internet]. Braga: University of Minho; 2025 Oct 27. https://www.engium.uminho.pt/en/uminho-announces-creation-of-therapeutic-phage-production-laboratory/
145. Pires DP, Rita Costa A, Pinto G, Meneses L, Azeredo J. Current challenges and future opportunities of phage therapy. FEMS Microbiol Rev. 2020;44(6):684–700. https://doi.org/10.1093/femsre/fuaa017 DOI: https://doi.org/10.1093/femsre/fuaa017
146. Pires DP, Meneses L, Brandão AC, Azeredo J. An overview of the current state of phage therapy for the treatment of biofilm-related infections. Curr Opin Virol. 2022;53:101209. https://doi.org/10.1016/j.coviro.2022.101209 DOI: https://doi.org/10.1016/j.coviro.2022.101209
147. Technophage. New INFARMED guidance on the use of phage therapy in the hospital context [Internet]. Lisbon: Technophage; 2024. https://technophage.pt/new-infarmed-guidance-on-the-use-of-phage-therapy-in-the-hospital-context/
148. LxBio. LxBio is the 1st Portuguese biopharmaceutical company to join PhageEU, strengthening our commitment to advancing bacteriophage research and innovation [Internet]. Lisbon: LxBio; 2025 Feb 4. https://www.lxbio.pt/noticiasprrpartnership-1
149. iMed.ULisboa. Phage Biology Research and Infection Control (PhaBRIC) Laboratory [Internet]. Lisbon: Instituto de Investigação do Medicamento, Universidade de Lisboa; 2025. https://imed.ulisboa.pt/labs/phage-biology-research-and-infection-control/
150. i3S. BeSurf – BioEngineered Surfaces Group [Internet]. Porto: Instituto de Investigação e Inovação em Saúde (i3S), University of Porto; 2025. https://www.i3s.up.pt/research-group.php?groupid=106
151. International Iberian Nanotechnology Laboratory (INL). Phages on Chip [Internet]. Braga: International Iberian Nanotechnology Laboratory; 2025. https://www.inl.int/projects/phages-on-chip/
Downloads
Publicado
Edição
Secção
Licença
Direitos de Autor (c) 2026 Joana Alves, Ana Cláudia Carvalho, Carlos Capela, Betânia Faria, Rosalina Leite, Luciana Meneses, Diana Priscila Pires, Joana Azeredo (Autor)
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
